Generation of minor histocompatibility antigen HA-1-specific cytotoxic T cells restricted by nonself HLA molecules: a potential strategy to treat relapsed leukemia after HLA-mismatched stem cell transplantation

被引:47
作者
Mutis, T
Blokland, E
Kester, M
Schrama, E
Goulmy, E
机构
[1] Leiden Univ, Med Ctr, Dept Immunohematol & Blood Transfus, NL-2333 ZA Leiden, Netherlands
[2] Leiden Univ, Med Ctr, Dept Hematol, NL-2333 ZA Leiden, Netherlands
关键词
D O I
10.1182/blood-2002-01-0024
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Successful stem cell transplantation (SCT) across HLA barriers can be performed with cord blood, megadoses of stem cells, or with nonmyeloablative conditioning strategies. Because the HLA-mismatched transplants are often T-cell depleted, leukemia relapse rates are high. Treatment of relapsed leukemia after HLA-mismatched SCT is difficult. A novel potential strategy to treat relapsed leukemia after HLA-mismatched SCT is the use of patients' mismatched HLA molecules as antigen-presenting molecules to generate hematopoietic system-specific cytotoxic T cells (CTLs) from the stem cell donor. Adoptive transfer of these hematopoetic system-specific CTLs that are restricted by nonself HLA molecules may eliminate leukemia without affecting the patient's nonhematopoietic cells or donor hematopoietic cells. We investigated the feasibility of this strategy using the hematopoletic system-specific minor histocompatibility antigen HA-1, which is known to induce HLA-A2-restricted CTLs. HLA-A2(-) peripheral blood mononuclear cells were stimulated with HLA-A2(+) T2 cells pulsed with synthetic HA-1 peptide or with dendritic cells transduced with the HA-1 cDNA. Tetrameric HLA-A2/HA-1 peptide complexes were used to monitor and enrich HA-1-specific CTLs. In the alloreactive cultures, HA-1-specific CTLs were enriched up to 7% by 3 rounds of antigen-specific stimulations and up to 87% by fluorescence-activated cell sorting of tetramer-positive T cells. The HA-1-specific CTLs showed specific lysis of the relevant target cells, including leukemic cells. Because the polyclonal CTL cultures also contained natural killer cells and allo-HLA-A2-specific CTLs, CTL clones were generated that showed the expected HA-1 specificity only. Thus, HA-1-specific CTLs restricted by nonself HLA-A2 molecules can be generated in an HLA-A2-mismatched setting.
引用
收藏
页码:547 / 552
页数:6
相关论文
共 26 条
[1]   Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype [J].
Aversa, F ;
Tabilio, A ;
Velardi, A ;
Cunningham, I ;
Terenzi, A ;
Falzetti, F ;
Ruggeri, L ;
Barbabietola, G ;
Aristei, C ;
Latini, P ;
Reisner, Y ;
Martelli, MF .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (17) :1186-1193
[2]  
Champlin R, 1993, J Hematother, V2, P27, DOI 10.1089/scd.1.1993.2.27
[3]   MINOR HISTOCOMPATIBILITY ANTIGENS, DEFINED BY GRAFT-VS-HOST DISEASE-DERIVED CYTOTOXIC LYMPHOCYTES-T, SHOW VARIABLE EXPRESSION ON HUMAN SKIN CELLS [J].
DEBUEGER, M ;
BAKKER, A ;
VANROOD, JJ ;
GOULMY, E .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1991, 21 (11) :2839-2844
[4]   The minor histocompatibility antigen HA-1: A diallelic gene with a single amino acid polymorphism [J].
den Haan, JMM ;
Meadows, LM ;
Wang, W ;
Pool, J ;
Blokland, E ;
Bishop, TL ;
Reinhardus, C ;
Shabanowitz, J ;
Offringa, R ;
Hunt, DF ;
Engelhard, VH ;
Goulmy, E .
SCIENCE, 1998, 279 (5353) :1054-1057
[5]   GROWTH-INHIBITION OF CLONOGENIC LEUKEMIC PRECURSOR CELLS BY MINOR HISTOCOMPATIBILITY ANTIGEN-SPECIFIC CYTOTOXIC LYMPHOCYTES-T [J].
FALKENBURG, JHF ;
GOSELINK, HM ;
VANDERHARST, D ;
VANLUXEMBURGHEIJS, SAP ;
KOOYWINKELAAR, YMC ;
FABER, LM ;
DEKROON, J ;
BRAND, A ;
FIBBE, WE ;
WILLEMZE, R ;
GOULMY, E .
JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 174 (01) :27-33
[6]   Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T lymphocytes specific for WT1 [J].
Gao, LQ ;
Bellantuono, I ;
Elsässer, A ;
Marley, SB ;
Gordon, MY ;
Goldman, JM ;
Stauss, HJ .
BLOOD, 2000, 95 (07) :2198-2203
[7]  
Gillespie G, 2000, Hematol J, V1, P403, DOI 10.1038/sj.thj.6200065
[8]   Outcome of cord-blood transplantation from related and unrelated donors [J].
Gluckman, E ;
Rocha, V ;
BoyerChammard, A ;
Locatelli, F ;
Arcese, W ;
Pasquini, R ;
Ortega, J ;
Souillet, G ;
Ferreira, E ;
Laporte, JP ;
Fernandez, M ;
Chastang, C .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (06) :373-381
[9]   Human minor histocompatibility antigens: New concepts for marrow transplantation and adoptive immunotherapy [J].
Goulmy, E .
IMMUNOLOGICAL REVIEWS, 1997, 157 :125-140
[10]  
HOROWITZ MM, 1990, BLOOD, V75, P555